You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK):實體瘤治療新藥獲藥品臨牀試驗申請受理
格隆匯 04-27 18:42

格隆匯4月27日丨復星醫藥(02196.HK)公佈,近日,公司控股子公司重慶復創醫藥研究有限公司(以下簡稱"復創醫藥")收到《受理通知書》(受理號:CXHL2000185 國、CXHL2000186 國),其研製的 FCN-011 膠囊(以下簡稱"該新藥")用於實體瘤治療獲國家藥品監督管理局(以下簡稱"國家藥監局")臨牀試驗註冊審評受理。

該新藥為集團(即公司及控股子公司/單位,下同)自主研發的創新型小分子化學藥物,擬主要用於實體瘤治療。截至公告日,在中國大陸境內尚無與該新藥同類型產品上市。截至 2020年3月,集團現階段針對該新藥累計研發投入為人民幣約 2,139 萬元(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account